When will Beam Therapeutics submit a BLA for Risto-cel?
16.0 pts (24h)Health & MedicineOne-OffScience1mois
KalshiVérifier la disponibilitéKYC requis2% de fraisDonnées de résolution vérifiéesAssez bien calibréProbabilité implicite actuelle
before April 2027 93%En tête parmi 6 options
Qualité du marché
44 / 100
Faible qualitéVolume 24h
1 k €
Liquidité
16,9 k €
Liquidité moyenneÉcart
87.0 pt
Spread largeDonnées du marché
Mis à jour il y a 2 minutes
24 mars 26, 14:00 UTC1 nov. 26, 05:00 UTC
Tendances
Marchés Associés
Questions liées pour le contexte, et non une comparaison de contrats équivalents.
FDA decision: Ivonescimab by Summit Therapeutics (in 2026)
KalshiFDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
KalshiWhen will Compass Pathways submit a NDA for COMP360 psilocybin?
KalshiWill we get AGI before 2028?
Manifold MarketsWill we get AGI before 2029?
Manifold MarketsWill aging be solved by EOY 2035?
Manifold MarketsRègles
If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Sep 1, 2026, then the market resolves to Yes.
- If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Oct 1, 2026, then the market resolves to Yes.
- If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Nov 1, 2026, then the market resolves to Yes.
- If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Dec 1, 2026, then the market resolves to Yes.
- If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Jan 1, 2027, then the market resolves to Yes.
- If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Apr 1, 2027, then the market resolves to Yes.
Marchés ouverts
Health & Medicine
POLYMARKETHantavirus pandemic in 2026?
- No97%
- Yes3%
- Volume total
- 15,6 M €
- Volume 24h
- 20,4 k €
POLYMARKETNew pandemic in 2026?
- No94.1%
- Yes5.9%
- Volume total
- 919 k €
- Volume 24h
- 4,2 k €
KALSHIMedtronic cardiovascular growth in Q2
- Above 8%92%
- Above 9%81%
- Above 11.5%53%
+6 résultats de plus
- Volume total
- 2,6 k €
- Volume 24h
- 2,6 k €
POLYMARKETMeasles cases in U.S. in 2026?
- ↑3.5k+0.1pt100%
- ↑500+0.1pt100%
- ↑1k+0.1pt100%
+9 résultats de plus
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 400097%
- Above 6000+3.0pt61%
+2 résultats de plus
- Volume total
- 866,7 k €
- Volume 24h
- 1,7 k €
KALSHIPandemic in 2026?
- No95%
- Yes5%
- Volume total
- 611,8 k €
- Volume 24h
- 1,1 k €
- Which countries will report an Ebola disease case before October?
- When will the FDA approve Intellia Therapeutics' lonvo-z?
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
- Heidi Overton confirmed as FDA Commissioner by which date?
- Will the FDA approve retatrutide?
- Ebola pandemic in 2026?
- Will WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- Measles cases in U.S. by September 30?
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- FDA approves Retatrutide this year?
Questions fréquentes
- Quelles sont les probabilités actuelles pour When will Beam Therapeutics submit a BLA for Risto-cel? ?
- Kalshi cote before April 2027 à 93% au 10 septembre 2026.
- Quand When will Beam Therapeutics submit a BLA for Risto-cel? sera-t-il résolu ?
- When will Beam Therapeutics submit a BLA for Risto-cel? doit être résolu le 1 novembre 2026.
- Comment When will Beam Therapeutics submit a BLA for Risto-cel? est-il réglé ?
- Kalshi règle ce marché comme suit : If Beam Therapeutics Inc. submits a BLA for Ristoglogene autogetemcel (risto-cel) to the FDA before Sep 1, 2026, then the market resolves to Yes.